Published in Ann Oncol on September 01, 1997
Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res (2008) 2.94
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol (2015) 1.73
Clinical relevance of single item quality of life indicators in cancer clinical trials. Br J Cancer (2001) 1.13
Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. Breast (2010) 1.09
Psychosocial predictors of outcome: time to relapse and survival in patients with early stage melanoma. Br J Cancer (2000) 1.02
Long-term quality of life in premenopausal women with node-negative localized breast cancer treated with or without adjuvant chemotherapy. Br J Cancer (2000) 0.99
Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer. Br J Cancer (2004) 0.88
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol (2016) 0.85
Many quality measurements, but few quality measures assessing the quality of breast cancer care in women: a systematic review. BMC Cancer (2006) 0.84
Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. Br J Cancer (2012) 0.82
Endocrine symptom assessment in women with breast cancer: what a simple "yes" means. Support Care Cancer (2007) 0.81
Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation? Support Care Cancer (2009) 0.79
Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. Br J Cancer (2007) 0.78
Electronic monitoring of symptoms and syndromes associated with cancer: methods of a randomized controlled trial SAKK 95/06 E-MOSAIC. BMC Palliat Care (2012) 0.75
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol (2011) 13.95
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol (2013) 9.68
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol (2009) 9.18
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet (2007) 8.08
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol (2007) 7.33
Analysis of survival by tumor response. J Clin Oncol (1983) 5.91
Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol (2005) 5.41
Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol (2001) 5.31
Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med (1991) 5.22
Redressing the balance--the ethics of not entering an eligible patient on a randomised clinical trial. Ann Oncol (1992) 4.41
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol (2002) 4.32
Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med (1995) 4.03
Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood (2001) 3.93
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet (2000) 3.79
Randomised comparison of procedures for obtaining informed consent in clinical trials of treatment for cancer. Br Med J (Clin Res Ed) (1986) 3.52
Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst (1998) 3.50
Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet (1999) 3.50
Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol (1996) 3.30
Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol (2004) 3.29
Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood (2001) 3.24
Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol (1992) 3.17
Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer (1998) 3.03
Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet (2008) 2.91
The Gothenburg breast screening trial: first results on mortality, incidence, and mode of detection for women ages 39-49 years at randomization. Cancer (1997) 2.75
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol (2006) 2.72
Changing character of cervical cancer in young women. BMJ (1989) 2.66
Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol (1989) 2.57
Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol (2001) 2.37
Who gets chemotherapy for metastatic lung cancer? Chest (2000) 2.27
Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann Oncol (2008) 2.26
A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med (2000) 2.17
Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. Cancer (1998) 2.12
Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer. J Clin Oncol (2001) 2.05
Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days. Ann Oncol (1998) 2.05
On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol (1996) 2.03
Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol (2002) 2.03
Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group. J Clin Oncol (1991) 2.02
Outcome of pregnancy in survivors of Wilms' tumor. JAMA (1987) 2.00
Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study Group. J Clin Oncol (1992) 2.00
Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol (1999) 1.98
A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group. N Engl J Med (1994) 1.97
1st International consensus guidelines for advanced breast cancer (ABC 1). Breast (2012) 1.96
Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol (2000) 1.92
Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol (2000) 1.91
Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. The International Breast Cancer Study Group. Ann Intern Med (1991) 1.88
Psychosocial predictors of survival in metastatic melanoma. J Clin Oncol (1999) 1.83
Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium. Cancer (1997) 1.82
Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. J Clin Oncol (2000) 1.81